Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Fludarabine, Busulfan and Alemtuzumab as a Reduced Toxicity Ablative Bone Marrow Stem Cell Transplant Regimen for Children With Stem Cell Defects, Marrow Failure Syndromes, or Myelodysplastic Syndrome (MDS)/Leukemia

NCT00301834 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.

NCT NCT00301834
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00301834 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Fludarabine, Busulfan and Alemtuzumab as a Reduced Toxicity Ablative Bone Marrow Stem Cell Transplant Regimen for Children With Stem Cell Defects, Marrow Failure Syndromes, or Myelodysplastic Syndrome (MDS)/Leukemia
Lead sponsor
University of California, San Francisco
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2005
Completion date
September 30, 2011
Enrollment
35 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

congenital amegakaryocytic thrombocytopenia, diamond-blackfan anemia, leukemia, myelodysplastic syndromes, severe congenital neutropenia